Sugi Predict

Sugi Predict / Compounds / SCHEMBL8622

SCHEMBL8622

SCHEMBL8622

CC(C)(O)C(C)(C)OB(O)c1ccc2[nH]ccc2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ENPP2 Q13822 1/20 0.41
▸ USP2 O75604 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ RAD51 Q06609 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ F2 P00734 1/20 0.39
▸ CYP1A2 P05177 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ AHR P35869 3/20 0.37
▸ NR4A2 P43354 2/20 0.37
▸ CYP2A6 P11509 2/20 0.37
▸ F7 P08709 1/20 0.37
▸ LTA4H P09960 1/20 0.37
▸ F3 P13726 1/20 0.37
▸ MAOA P21397 2/20 0.35
▸ IMPDH2 P12268 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14720450 0.89 ENPP2 (0.55) ENPP2MAPTAHRCYP2A6MAOA
SCHEMBL2350927 0.79 AXL (0.42) ALOX15MAPTRAB9ACYP2A6MAOA
SCHEMBL1795397 0.79 F2 (0.49) ENPP2USP2GAAALOX15RAD51
SCHEMBL8835 0.78 ROCK1 (0.41) GAAMAPTRAB9ANPC1MAOB
SCHEMBL28190471 0.77 ENPP2 (0.41) ENPP2USP2GAAALOX15RAD51
SCHEMBL189856 0.77 RIPK1 (0.40) —
SCHEMBL517925 0.76 CA1 (0.50) F2CYP1A2CYP2A6
SCHEMBL8892 0.75 ATM (0.36) NR4A2
SCHEMBL2361665 0.75 MMP12 (0.34) MAPT
SCHEMBL1128777 0.75 ESR1 (0.36) ENPP2ALOX15CYP1A2CYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122010656-A Application of oxyalkylisourea in introducing methyl and isotopically-labeled methyl 陕西师范大学 2026-05-12 — — CN disclosed
CN-122010936-A Multi-kinase inhibitor, PROTACs target protein ligand, and synthesis method and application thereof 杭州医学院 2026-05-12 — — CN disclosed
EP-4628489-A1 7-AZAINDOLE COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF Fudan University (CN) 2025-10-08 — — EP disclosed
US-20250289809-A1 COMPOUNDS USEFUL FOR GOUT ATOM BIOSCIENCE AMERICA CORPORATION (US) 2025-09-18 — — US disclosed
CN-119661539-A Pan KRAS inhibitors and uses thereof 上海交通大学 2025-03-21 — — CN disclosed
EP-4516788-A1 COMPOUND CAPABLE OF BEING USED FOR GOUT Atom Therapeutics Co., Ltd (CN) 2025-03-05 — — EP disclosed
US-20240360095-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2024-10-31 — — US disclosed
CN-118812503-A Heterocyclic compounds as AAK1 inhibitors 艾立康药业股份有限公司 2024-10-22 — — CN disclosed
CN-118126036-A 7-Azaindole compound and preparation method and application thereof 复旦大学 2024-06-04 — — CN disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 — — US disclosed
WO-2013040059-A1 NOVEL IMIDAZOLE AMINES AS MODULATORS OF KINASE ACTIVITY MERCK PATENT GMBH (DE) 2013-03-21 — — WO disclosed
WO-2013028445-A1 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-02-28 — — WO disclosed
EP-2538784-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS Merck Sharp & Dohme Corp. (US) 2013-01-02 — — EP disclosed
US-20120309736-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS MERCK SHARP & DONME CORP 2012-12-06 — — US disclosed
EP-2496567-A2 NOVEL BENZOPYRAN KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2012-09-12 — — EP disclosed
WO-2012078777-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2012-06-14 — — WO disclosed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 — — US disclosed
WO-2011106273-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS MERCK SHARP & DOHME CORP. (US) 2011-09-01 — — WO disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 — — US disclosed
WO-2011055215-A2 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2011-05-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250289809-A1 COMPOUNDS USEFUL FOR GOUT SLC10A1, ABCG2, SLC10A6 ENPP2 140/4885USP2 2292/4885GAA 216/4885
US-20120309736-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS PRKAG2, PRKAG1, PRKAB2 ENPP2 3148/4885USP2 2598/4885GAA 606/4885
US-20240360095-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB ENPP2 739/4885USP2 1677/4885GAA 1215/4885
US-20110118257-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB ENPP2 739/4885USP2 1677/4885GAA 1215/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A ENPP2 463/4885USP2 3228/4885GAA 2866/4885
US-20120059001-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB ENPP2 739/4885USP2 1677/4885GAA 1215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.